Journal article
Using Apolipoprotein B to Manage Dyslipidemia
Mayo Clinic proceedings, Vol.85(8), pp.769-769
2010
DOI: 10.4065/mcp.2010.0287
PMCID: PMC2912744
PMID: 20675517
Abstract
To the Editor: In their commentary on using apolipoprotein (apo) B to manage dyslipidemia, Harper and Jacobson1 advocate supplanting low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C) with apo B for risk assessment and as targets of therapy. Unfortunately, their enthusiasm for apo B is not supported by currently available evidence. In a recent meta-analysis of more than 90,000 individuals in 22 prospective cohort studies performed by the Emerging Risk Factor Collaboration, apo B was not superior to non–HDL-C.2 Nor has apo B been shown to be superior to non–HDL-C for predicting risk in statin-treated individuals.3,4 As Lavie et al5 correctly observe in their commentary, we currently lack clinical trial evidence that treatment intensification based on apo B levels in patients with LDL-C and non–HDL-C at goal results in improved clinical outcomes. Such trials are needed to support more aggressive lipid treatment strategies than are currently recommended.
Details
- Title: Subtitle
- Using Apolipoprotein B to Manage Dyslipidemia
- Creators
- Jennifer Robinson
- Resource Type
- Journal article
- Publication Details
- Mayo Clinic proceedings, Vol.85(8), pp.769-769
- DOI
- 10.4065/mcp.2010.0287
- PMID
- 20675517
- PMCID
- PMC2912744
- ISSN
- 0025-6196
- eISSN
- 1942-5546
- Language
- English
- Date published
- 2010
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center; Internal Medicine
- Record Identifier
- 9983996097302771
Metrics
14 Record Views